The Ministry of Food and Drug Safety (Minister Oh Yoo-Kyung) approved BMS Korea's new plaque psoriasis drug 'Sotyktu 6mg' on the 3rd.

Psoriasis is a chronic skin disease caused by immune abnormalities, and plaque psoriasis is the most common form. Sotyktu treats psoriasis by selectively inhibiting 'tyrosine kinase-2 (TYK2)' receptors related to inflammation and immune response by oral administration.

The drug was approved by the US FDA in 2022 for use in adult patients with moderate to severe psoriasis who require systemic therapy or phototherapy. Sotyktu is the world's first and only TYK2 inhibitor approved for use and is the first oral drug available for moderate to severe psoriasis in